Video

Dr. Bota on Marizomib in Patients with Glioma

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.

There are a few very important characteristics of this agent, Bota says, the first of which is that marizomib has demonstrated positive results in multiple glioma studies, both in vitro and in vivo. Next, the emerging drug seems to be effective in eradicating glioblastoma stem cells—the target for which it appears to have the most affinity. In preclinical studies, data show that marizomib can stop tumor growth.

Additionally, the agent is an irreversible proteasome inhibitor, meaning that once it binds to proteasome molecules and removes them, they cannot be recovered. This is in contrast to some of the more common reversible proteasome inhibitors. Marizomib can also target all 3 units of the proteasome.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD